Virbac VIRP.PA
Virbac is a French pharmaceutical company specializing in animal health, developing and marketing medicines, vaccines, and supplements for companion animals and livestock worldwide. Virbac shows solid fundamentals with ROIC of 18.18%, gross margin of 67.21% and net debt/EBITDA of only 0.65, although growth is moderate (revenue +4.0%) and momentum is weak (16th percentile in 52 weeks).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Virbac is a French pharmaceutical company specializing in animal health, developing and marketing medicines, vaccines, and supplements for companion animals and livestock worldwide. Virbac shows solid fundamentals with ROIC of 18.18%, gross margin of 67.21% and net debt/EBITDA of only 0.65, although growth is moderate (revenue +4.0%) and momentum is weak (16th percentile in 52 weeks).
Score by category
| Category | Score |
|---|---|
| Financial health | 7.5 |
| Quality / Moat | 7.1 |
| Valuation | 6.2 |
| Growth | 5.5 |
| Dividend | 2.9 |
| Momentum | 3.0 |
| Risk & Context | 6.2 |
OVERALL SCORE: 6.0/10
Context and risks
Elevated governance risk in France and currency exposure (FX effect mentioned in news) that could affect margins. However, the animal health business is defensive and has no direct exposure to rates, energy or geopolitics.
News considered in the analysis
- Virbac shares jump on Q1 growth as North America surge offsets FX drag — Crecimiento en Norteamérica compensa el lastre cambiario, señal positiva de demanda en un mercado clave.
- A Look At Virbac (ENXTPA:VIRP) Valuation As Shares Ease Despite Longer Term Gains — Artículo de valoración genérico sin información nueva.
- Assessing Virbac (ENXTPA:VIRP) Valuation As Investors Revisit The Stock’s Recent Performance — Listículo de valoración sin datos concretos.
- Is Virbac (ENXTPA:VIRP) Offering Value After Strong Multi Year Share Price Gains — Análisis retrospectivo sin catalizador nuevo.
- How Analyst Optimism Is Changing the Growth Story for Virbac — Optimismo de analistas sugiere revisión al alza de expectativas, aunque no es un hecho consumado.
Verdict: Hold; reasonable valuation and conservative balance sheet, but no clear short-term growth catalysts.
Main risk: Exposure to currency fluctuations (FX effect) that could erode margins in markets outside Europe.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →